OR WAIT null SECS
The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
April 16, 2020
The lab is expected to open in April 2020 and will increase the company’s capacity for diagnostic testing of rare genetic diseases along with its COVID-19 capabilities.
The guidance document describes the agency’s temporary policy for the compounding of drugs during the COVID-19 pandemic.
Experts to discuss strategies for ensuring supply of quality drug products during a pandemic in April 28 online event.
April 15, 2020
AstraZeneca has announced it will be commencing a randomized, global clinical trial to assess the efficacy and safety of Calquence (acalabrutinib) in treating the exaggerated immune response of patients with COVID-19.
Sanofi and GlaxoSmithKline (GSK) have revealed that they are joining forces to develop an adjuvanted vaccine using their respective technologies that can be used to fight COVID-19.
The agency sent warning letters to three more companies for selling unapproved products claiming to treat COVID-19.
April 13, 2020
Drug manufacturers, distributors, and dispensers oppose Buy American policies as likely to reduce reliable supplies and raise product costs.
April 10, 2020
The task force will assist in the developing, authorizing, and monitoring of treatments of COVID-19.
The guidance answers questions on changes made to the regulatory framework to address challenges during the COVID-19 pandemic.
April 09, 2020
The company is advancing its lung-selective nebulized Janus kinase inhibitor into clinical development to determine its ability to prevent acute lung injury in patients with COVID-19.